{"filing":{"accession_number":"0001654954-26-005913","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-06-12","report_date":null,"primary_document":"a0204i.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426005913/a0204i.htm"},"events":[{"id":12186,"run_id":10749,"accession_number":"0001654954-26-005913","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M\u0026A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":8973,"accession_number":"0001654954-26-005913","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M\u0026A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:22:16.801216+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-06-12"}]}